Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -8.73% | +4.55% | -66.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.76% | 6.07Cr | |
-2.99% | 8.95TCr | |
+2.50% | 4.07TCr | |
-12.01% | 3.32TCr | |
+63.43% | 2.65TCr | |
-19.79% | 1.47TCr | |
-8.58% | 1.29TCr | |
-12.34% | 1.15TCr | |
-43.92% | 1.13TCr | |
+3.75% | 884.15Cr |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site